Video

Dr. Patel on the FDA Approval of Durvalumab in NSCLC

Author(s):

Jyoti D. Patel, MD

In Partnership With:

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non—small cell lung cancer (NSCLC).

Related Videos
Jorge E. Cortes, MD
Nicolas Girard, MD
Sunil Adige, MD
Minoo Battiwalla, MD, MS
Samuel J. Klempner, MD
Jill Corre, PharmD, PhD
Chad Tang, MD
Grzegorz S. Nowakowski, MD, consultant, Division of Hematology, Department of Internal Medicine, enterprise deputy director, Clinical Research, professor, oncology, medicine, Mayo Clinic Comprehensive Cancer Center
Leo I. Gordon, MD
Terence W. Friedlander, MD
Related Content
The OncFive
October 19th 2024

The OncFive: Top Oncology News and Trends for the Week of 10/13

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Hidehito Horinouchi, MD, PhD
October 18th 2024

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

FDA
October 15th 2024

FDA Approves Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy

Luis Paz-Ares, MD, PhD
October 15th 2024

Lurbinectedin/Atezolizumab Combination Improves Survival in ES-SCLC